Two doses of Johnson & Johnson’s Covid-19 vaccine provided up to 85 percent protection against hospitalization from the Omicron variant, researchers in South Africa have reported.
The study from the South African Medical Research Council evaluated a second booster shot in 69,092 health care workers from November 15 to December 20. Researchers observed that effectiveness preventing hospitalization rose from 63 percent to 84 percent within 14 days and then 85 percent one to two months post-boost.
The researchers went on to say that these results mark the first evidence of the effectiveness of such a vaccine boost while Omicron is circulating and are important considering the increased reliance on the J&J vaccine in Africa, where the virus strain was first observed. The study has not been peer-reviewed.
The Food and Drug Administration authorized J&J boosters in October as part of a broader expansion of the country’s booster campaign heading into the fall and winter. All J&J recipients who are at least two months past their shot may get a booster, a recognition of that vaccine’s lower efficacy compared to the Pfizer-BioNTech and Moderna Covid shots. The one-dose J&J vaccine is authorized for people 18 and older.
However, J&J’s shot has had limited uptake in the U.S. since the federal government paused its use in April over concerns about blood clotting post-inoculation. The company’s U.S. production was also interrupted for months by problems at a contractor’s plant.
J&J said prior to the emergence of Omicron, in October, that giving a second dose two months after the first increased protection against symptomatic moderate to severe Covid-19 to 94 percent, with 100 percent protection against severe illness.
Vaccine manufacturers and the Biden administration are continuing to evaluate whether booster shots should be considered part of the original Covid-19 vaccine regimen as the Omicron strain rapidly spreads across the country.
—
Photo Credit: vovidzha / Shutterstock.com